Sickle Cell Disease Drug Market By Drug Type ( Antibiotics, Hydroxyurea, Pain-relieving medications ), By Mode of Administration ( Oral, Intravenous ), By Disease Type ( Sickle cell anemia, Sickle beta thalassemia, Sickle hemoglobin c disease ), By Distribution Channel ( Retail pharmacies, Hospital pharmacies, Online pharmacies ), Industry Trends, Estimation & Forecast, 2017 - 2025

  • Published On: Apr, 2018
  • Category: Healthcare
  • Pages: 184
Sickle Cell Disease Drug Market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.

Market Overview:

Sickle cell disease refers to a set of inherited diseases that cause the transformation of disc shaped red blood cells into a sickle shaped cells. It is an umbrella term for disease such as sickle cell anemia, sickle hemoglobin C disease, and sickle beta thalassemia. Numerous developments occurring in the industry related to sickle cell disease has led the sickle cell disease drug market to emerge as a lucrative market. Market players are continuously striving to achieve success in developing a permanent drug that can cure the disease. The global sickle cell disease drug market is experiencing hurdles in its growth, owing to the unavailability of drugs in the rural areas of developing nations, malpractices occurring in drug sales, and availability of few FDA approved drugs for sickle cell anemia. In terms of geography, the Middle East and Africa, South America, India are the most lucrative pockets as they are the regions with high prevalence of occurrence of sickle cell disease. The report provides detailed qualitative and quantitative analysis of the global sickle cell disease drug market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely drug type, mode of administration, disease type, and distribution channel in each of the major regions of the world.

Sickle Cell Disease Drug Market Segmentation

By Drug Type • Antibiotics • Hydroxyurea • Pain-relieving medications • Others By Mode of Administration • Oral • Intravenous By Disease Type • Sickle cell anemia • Sickle beta thalassemia • Sickle hemoglobin c disease By Distribution Channel • Retail pharmacies • Hospital pharmacies • Online pharmacies By Geography • North America o U.S. o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION 1.1. RESEARCH METHODOLOGY 1.1.1. ERC desk research 1.1.2. ERC data synthesis 1.1.3. Data validation and market feedback 1.1.4. ERC data sources CHAPTER 2. SICKLE CELL DISEASE DRUG MARKET OVERVIEW 2.1. SICKLE CELL DISEASE DRUG MARKET INTRODUCTION 2.2. GLOBAL SICKLE CELL DISEASE DRUG MARKET PRODUCTION AND GROWTH RATE, 2017-2025 2.2.1. Global Sickle Cell Disease Drug Production (VOLUME) and Growth Rate (%), (2017-2025) 2.3. GLOBAL SICKLE CELL DISEASE DRUG MARKET CAPACITY AND GROWTH RATE, 2017-2025 2.3.1. Global Sickle Cell Disease Drug Capacity (VOLUME) and Growth Rate (%), (2017-2025) 2.4. GLOBAL SICKLE CELL DISEASE DRUG MARKET REVENUE AND GROWTH RATE, 2017-2025 2.4.1. Global Sickle Cell Disease Drug Market Revenue (Million USD) and Growth Rate (%), (2017-2025) 2.5. GLOBAL SICKLE CELL DISEASE DRUG MARKET CONSUMPTION AND GROWTH RATE, 2017-2025 2.5.1. Global Sickle Cell Disease Drug Consumption (VOLUME) and Growth Rate (%), (2017-2025) 2.6. GLOBAL SICKLE CELL DISEASE DRUG MARKET PRICE TREND, 2017-2025 2.6.1. Global Sickle Cell Disease Drug Market Price Trend and Growth Rate (%), (2017-2025) CHAPTER 3. GLOBAL SICKLE CELL DISEASE DRUG MARKET BY DRUG TYPE, 2017-2025 3.1. ANTIBIOTICS 3.2. PAIN-RELIEVING MEDICATIONS 3.3. HYDROXYUREA 3.4. GLOBAL SICKLE CELL DISEASE DRUG MARKET REVENUE BY DRUG TYPE, 2017-2025 3.4.1. Global Sickle Cell Disease Drug Market Revenue (Million USD) and Share (%) By Drug type, 2017-2025 3.4.2. Antibiotics Market Revenue and Growth Rate, 2017-2025 3.4.3. Pain-relieving medications Market Revenue and Growth Rate, 2017-2025 3.4.4. Hydroxyurea Market Revenue and Growth Rate, 2017-2025 3.5. GLOBAL SICKLE CELL DISEASE DRUG MARKET PRODUCTION BY DRUG TYPE, 2017-2025 3.5.1. Global Sickle Cell Disease Drug Market Production (Volume) and Share (%) By Drug type, 2017-2025 3.5.2. Antibiotics Market Production and Growth Rate, 2017-2025 3.5.3. Pain-relieving medications Market Production and Growth Rate, 2017-2025 3.5.4. Hydroxyurea Market Production and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for mode of administration segment. CHAPTER 4. GLOBAL SICKLE CELL DISEASE DRUG MARKET BY DISEASE TYPE, 2017-2025 4.1. SICKLE CELL ANEMIA 4.2. SICKLE BETA THALASSEMIA 4.3. SICKLE HEMOGLOBIN C DISEASE 4.4. GLOBAL SICKLE CELL DISEASE DRUG MARKET REVENUE BY DISEASE TYPE, 2017-2025 4.4.1. Global Sickle Cell Disease Drug Market Revenue (Million USD) and Share (%) By Disease type, 2017-2025 4.4.2. Sickle cell anemia Market Revenue and Growth Rate, 2017-2025 4.4.3. Sickle beta thalassemia Market Revenue and Growth Rate, 2017-2025 4.4.4. Sickle hemoglobin c disease Market Revenue and Growth Rate, 2017-2025 4.5. GLOBAL SICKLE CELL DISEASE DRUG MARKET CONSUMPTION BY DISEASE TYPE, 2017-2025 4.5.1. Global Sickle Cell Disease Drug Market Consumption (Volume) and share (%) By Disease type, 2017-2025 4.5.2. Sickle cell anemia Market Consumption and Growth Rate, 2017-2025 4.5.3. Sickle beta thalassemia Market Consumption and Growth Rate, 2017-2025 4.5.4. Sickle hemoglobin c disease Market Consumption and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for distributed channel segment. CHAPTER 5. GLOBAL SICKLE CELL DISEASE DRUG MARKET BY REGION, 2017-2025 5.1. NORTH AMERICA 5.1.1. U.S. 5.1.2. Canada 5.1.3. Mexico 5.2. EUROPE 5.2.1. U.K. 5.2.2. France 5.2.3. Germany 5.2.4. Italy 5.2.5. Spain 5.2.6. Rest of Europe 5.3. ASIA PACIFIC 5.3.1. China 5.3.2. Japan 5.3.3. India 5.3.4. Korea 5.3.5. Rest of APAC 5.4. SOUTH AMERICA 5.4.1. Brazil 5.4.2. Rest of South America 5.5. REST OF THE WORLD 5.5.1. Middle East 5.5.2. Africa 5.6. GLOBAL SICKLE CELL DISEASE DRUG MARKET REVENUE BY REGION, 2017-2025 5.6.1. Global Sickle Cell Disease Drug Market Revenue (Million USD) and Share (%) By Region, 2017-2025 5.6.2. North America Market Revenue and Growth Rate, 2017-2025 5.6.3. Europe Market Revenue and Growth Rate, 2017-2025 5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025 5.6.5. South America Market Revenue and Growth Rate, 2017-2025 5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025 CHAPTER 6. GLOBAL SICKLE CELL DISEASE DRUG MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025 6.1. GLOBAL SICKLE CELL DISEASE DRUG MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025 6.1.1. Global Sickle Cell Disease Drug Market Production (Volume) and Share (%) By Region, 2017-2025 6.1.2. Global Sickle Cell Disease Drug Market Consumption (Volume) and Share (%) By Region, 2017-2025 6.1.3. North America Market Production and Consumption, 2017-2025 6.1.4. Europe Market Production and Consumption, 2017-2025 6.1.5. Asia Pacific Market Production and Consumption, 2017-2025 6.1.6. South America Market Production and Consumption, 2017-2025 6.1.7. Rest of the World Market Production and Consumption, 2017-2025 CHAPTER 7. MARKET DETERMINANTS 7.1. MARKET DRIVERS 7.2. MARKET RESTRAINTS 7.3. MARKET OPPORTUNITIES 7.4. MARKET DETERMINANTS RADAR CHART CHAPTER 8. GLOBAL SICKLE CELL DISEASE DRUG MARKET COMPETITION BY MANUFACTURERS 8.1. GLOBAL SICKLE CELL DISEASE DRUG PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025) 8.1.1. Global Sickle Cell Disease Drug Production (VOLUME) and Share (%) by Manufacturers (2017-2025) 8.2. GLOBAL SICKLE CELL DISEASE DRUG REVENUE AND SHARE BY MANUFACTURERS (2017-2025) 8.2.1. Global Sickle Cell Disease Drug Revenue (Million USD) and Share (%) by Manufacturers (2017-2025) 8.3. SICKLE CELL DISEASE DRUG MARKET COMPETITIVE SITUATION AND TRENDS 8.3.1. Sickle Cell Disease Drug Market Share (%) of Top 3 Manufacturers 8.3.2. Sickle Cell Disease Drug Market Share (%) of Top 5 Manufacturers CHAPTER 9. GLOBAL SICKLE CELL DISEASE DRUG MANUFACTURERS ANALYSIS 9.1. ACCELERON PHARMA 9.1.1. Business Overview 9.1.2. Company Basic Information 9.1.3. Sickle Cell Disease Drug Product Details 9.1.4. Acceleron Pharma Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.2. EPIDESTINY 9.2.1. Business Overview 9.2.2. Company Basic Information 9.2.3. Sickle Cell Disease Drug Product Details 9.2.4. Epidestiny Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.3. ERRANT GENE THERAPEUTICS 9.3.1. Business Overview 9.3.2. Company Basic Information 9.3.3. Sickle Cell Disease Drug Product Details 9.3.4. Errant Gene Therapeutics Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.4. GAMIDA CELL 9.4.1. Business Overview 9.4.2. Company Basic Information 9.4.3. Sickle Cell Disease Drug Product Details 9.4.4. Gamida Cell Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.5. PFIZER INC. 9.5.1. Business Overview 9.5.2. Company Basic Information 9.5.3. Sickle Cell Disease Drug Product Details 9.5.4. Pfizer Inc. Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.6. GLOBAL BLOOD THERAPEUTICS 9.6.1. Business Overview 9.6.2. Company Basic Information 9.6.3. Sickle Cell Disease Drug Product Details 9.6.4. Global Blood Therapeutics Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.7. HILLHURST BIOPHARMACEUTICALS 9.7.1. Business Overview 9.7.2. Company Basic Information 9.7.3. Sickle Cell Disease Drug Product Details 9.7.4. Hillhurst Biopharmaceuticals Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.8. NOVARTIS 9.8.1. Business Overview 9.8.2. Company Basic Information 9.8.3. Sickle Cell Disease Drug Product Details 9.8.4. Novartis Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.9. BLUEBIRD BIO, INC. 9.9.1. Business Overview 9.9.2. Company Basic Information 9.9.3. Sickle Cell Disease Drug Product Details 9.9.4. Bluebird bio, Inc. Sickle Cell Disease Drug Production, Revenue and Gross Margin 9.10. REGENACY PHARMACEUTICALS 9.10.1. Business Overview 9.10.2. Company Basic Information 9.10.3. Sickle Cell Disease Drug Product Details 9.10.4. Regenacy Pharmaceuticals Sickle Cell Disease Drug Production, Revenue and Gross Margin CHAPTER 10. SICKLE CELL DISEASE DRUG MARKET VALUE CHAIN ANALYSIS 10.1. SICKLE CELL DISEASE DRUG INDUSTRIAL CHAIN ANALYSIS 10.2. SICKLE CELL DISEASE DRUG KEY RAW MATERIALS ANALYSIS 10.2.1. Key Raw Materials 10.2.2. Price Trend of Key Raw Materials 10.2.3. Key Suppliers of Raw Materials 10.3. MARKETING CHANNEL 10.3.1. Direct Marketing 10.3.2. Indirect Marketing 10.3.3. Distributors/Traders 10.4. CONSUMER ANALYSIS 10.4.1. Consumer 1 10.4.2. Consumer 2 10.4.3. Consumer 3 10.4.4. Consumer 4

• Acceleron Pharma
• Epidestiny
• Errant Gene Therapeutics
• Gamida Cell
• Pfizer Inc.
• Global Blood Therapeutics
• Hillhurst Biopharmaceuticals
• Novartis
• bluebird bio, Inc.
• Regenacy Pharmaceuticals

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS